Vanguard FTSE Developed Europe UCITS ETF (LON:VEUA)
London · Delayed Price · Currency is GBP | Assets | 1.47B |
| Expense Ratio | 0.10% |
| PE Ratio | 16.22 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +14.50% |
| Volume | 42,133 |
| Open | 43.68 |
| Previous Close | 43.78 |
| Day's Range | 43.42 - 44.46 |
| 52-Week Low | 34.91 |
| 52-Week High | 44.46 |
| Beta | 0.88 |
| Holdings | 524 |
| Inception Date | Jul 23, 2019 |
About VEUA
Vanguard FTSE Developed Europe UCITS ETF is an exchange traded fund launched by Vanguard Group (Ireland) Limited. It is co-managed by Vanguard Asset Management, Limited and The Vanguard Group, Inc. It invests in the public equity markets of developed countries in Europe. The fund seeks to invest in the stocks of companies operating across diversified sectors. It invests in the stocks of large-cap and mid-cap companies. The fund seeks to replicate the performance of the FTSE Developed Europe Index, by investing in the stocks of companies as per their weightings in the index. Vanguard FTSE Developed Europe UCITS ETF was formed on May 21, 2013 and is domiciled in Ireland.
Performance
VEUA had a total return of 14.50% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.53%.
Top 10 Holdings
17.96% of assets| Name | Symbol | Weight |
|---|---|---|
| SAP SE | SAP | 2.38% |
| ASML Holding N.V. | ASML | 2.22% |
| AstraZeneca PLC | AZN | 1.81% |
| Roche Holding AG | ROG | 1.79% |
| Nestlé S.A. | NESN | 1.79% |
| Novartis AG | NOVN | 1.75% |
| HSBC Holdings plc | HSBA | 1.74% |
| Shell plc | SHEL | 1.73% |
| Siemens Aktiengesellschaft | SIE | 1.52% |
| Novo Nordisk A/S | NOVO.B | 1.24% |